Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2023 21:06 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
March 30, 2023 16:01 ET | Source: Nkarta, Inc.

Nkarta Announces Departure of Chief Financial & Business Officer

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...
March 16, 2023 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 ...
February 09, 2023 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
January 09, 2023 16:30 ET | Source: Nkarta, Inc.

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
December 05, 2022 07:02 ET | Source: Nkarta, Inc.

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle...
December 02, 2022 16:02 ET | Source: Nkarta, Inc.

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
November 09, 2022 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019...
November 07, 2022 08:52 ET | Source: Nkarta, Inc.

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of...
November 02, 2022 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...